Wang Shuhui, Allauzen Alexandre, Nghe Philippe, Opuu Vaitea
Laboratoire de Biophysique et Evolution, UMR CNRS-ESPCI 8231 Chimie Biologie Innovation, PSL University, Paris, France.
LAMSADE, Universite Paris-Dauphine, PSL University, Paris, France.
Sci Rep. 2025 Jan 28;15(1):3484. doi: 10.1038/s41598-025-85600-3.
Synergistic drug combination screening is a promising strategy in drug discovery, but it involves navigating a costly and complex search space. While AI, particularly deep learning, has advanced synergy predictions, its effectiveness is limited by the low occurrence of synergistic drug pairs. Active learning, which integrates experimental testing into the learning process, has been proposed to address this challenge. In this work, we explore the key components of active learning to provide recommendations for its implementation. We find that molecular encoding has a limited impact on performance, while the cellular environment features significantly enhance predictions. Additionally, active learning can discover 60% of synergistic drug pairs with only exploring 10% of combinatorial space. The synergy yield ratio is observed to be even higher with smaller batch sizes, where dynamic tuning of the exploration-exploitation strategy can further enhance performance. The code can be found at https://github.com/LBiophyEvo/DrugSynergy.
协同药物组合筛选是药物发现中一种很有前景的策略,但它涉及在一个成本高昂且复杂的搜索空间中进行探索。虽然人工智能,尤其是深度学习,已经改进了协同作用预测,但其有效性受到协同药物对出现频率低的限制。主动学习将实验测试整合到学习过程中,已被提出来应对这一挑战。在这项工作中,我们探索了主动学习的关键组成部分,为其实施提供建议。我们发现分子编码对性能的影响有限,而细胞环境特征显著增强了预测。此外,主动学习仅通过探索10%的组合空间就能发现60%的协同药物对。在较小的批次大小下,协同产量比甚至更高,在此情况下,对探索-利用策略进行动态调整可以进一步提高性能。代码可在https://github.com/LBiophyEvo/DrugSynergy上找到。